Identification

Name
Bepridil
Accession Number
DB01244  (APRD00727)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).

Structure
Thumb
Synonyms
  • Bepadin
  • Bepridil
Product Ingredients
IngredientUNIICASInChI Key
Bepridil hydrochloride4W2P15D93M74764-40-2UEECHQPWQHYEDE-UHFFFAOYSA-N
International/Other Brands
Angopril / Cordium / Vascor
Categories
UNII
755BO701MA
CAS number
64706-54-3
Weight
Average: 366.5396
Monoisotopic: 366.26711372
Chemical Formula
C24H34N2O
InChI Key
UIEATEWHFDRYRU-UHFFFAOYSA-N
InChI
InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
IUPAC Name
N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline
SMILES
CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1

Pharmacology

Indication

For the treatment of hypertension, and chronic stable angina (classic effort-associated angina).

Structured Indications
Not Available
Pharmacodynamics

Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride.

Mechanism of action

Bepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.

TargetActionsOrganism
AVoltage-dependent P/Q-type calcium channel subunit alpha-1A
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
USodium/potassium-transporting ATPase subunit alpha-1
inhibitor
Human
UPotassium voltage-gated channel subfamily KQT member 1
inhibitor
Human
UTroponin C, slow skeletal and cardiac muscles
other
Human
UCalmodulin
binder
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
inhibitor
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
Absorption

Rapidly and completely absorbed after oral administration.

Volume of distribution
Not Available
Protein binding

99%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

24-50 hours

Clearance
Not Available
Toxicity

There has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Bepridil.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Bepridil.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bepridil.Experimental
AbirateroneThe serum concentration of Bepridil can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Bepridil is combined with Acebutolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bepridil.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Bepridil is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Bepridil.Approved, Investigational
AliskirenBepridil may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
AmbrisentanBepridil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineBepridil may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Bepridil is combined with Amiloride.Approved
AmiodaroneThe metabolism of Bepridil can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Bepridil.Approved
AmobarbitalThe metabolism of Bepridil can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Bepridil.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Bepridil.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bepridil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bepridil is combined with Amyl Nitrite.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Bepridil.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bepridil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Bepridil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bepridil.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bepridil.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Bepridil.Approved
AtenololThe risk or severity of adverse effects can be increased when Bepridil is combined with Atenolol.Approved
AtomoxetineThe metabolism of Bepridil can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Bepridil is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Bepridil is combined with Atosiban.Approved, Investigational
Atracurium besylateBepridil may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Bepridil.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bepridil is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Bepridil.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Bepridil.Experimental
BarbitalThe metabolism of Bepridil can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bepridil.Approved
BenazeprilBenazepril may increase the hypotensive activities of Bepridil.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bepridil.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bepridil.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Bepridil.Approved
BetaxololThe metabolism of Bepridil can be decreased when combined with Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Bepridil.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Bepridil.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Bepridil.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Bepridil.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Bepridil.Approved
BoceprevirThe serum concentration of Bepridil can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bepridil is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Bepridil.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bepridil.Approved
BQ-123Bepridil may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Bepridil.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bepridil.Approved
BretyliumBretylium may increase the hypotensive activities of Bepridil.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bepridil.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Bepridil.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bepridil is combined with Bromocriptine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Bepridil.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bepridil is combined with Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Bepridil.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Bupivacaine.Approved, Investigational
BupranololBepridil may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Bepridil can be decreased when combined with Bupropion.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Bepridil.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Bepridil.Approved
CadralazineCadralazine may increase the hypotensive activities of Bepridil.Experimental
CafedrineBepridil may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Bepridil is combined with Canagliflozin.Approved
CandesartanBepridil may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Bepridil.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Bepridil.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Bepridil.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Bepridil.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Bepridil.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Bepridil is combined with Carbetocin.Approved
CarbomycinThe metabolism of Bepridil can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Bepridil.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Bepridil.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Bepridil.Approved, Investigational
CaseinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Bepridil.Approved
CelecoxibThe metabolism of Bepridil can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololBepridil may increase the hypotensive activities of Celiprolol.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Bepridil is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Bepridil.Approved
ChloroquineThe metabolism of Bepridil can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Bepridil.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Bepridil is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bepridil.Approved
CholecalciferolThe metabolism of Bepridil can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineBepridil may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Bepridil.Approved, Investigational
CilazaprilBepridil may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Bepridil can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Bepridil can be decreased when combined with Cinacalcet.Approved
CisaprideCisapride may increase the QTc-prolonging activities of Bepridil.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Bepridil can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Bepridil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bepridil can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clevidipine.Approved
ClobazamThe metabolism of Bepridil can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clofarabine.Approved, Investigational
ClomipramineThe metabolism of Bepridil can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bepridil.Approved, Nutraceutical
CloranololBepridil may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Bepridil.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clozapine.Approved
CobicistatThe serum concentration of Bepridil can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Bepridil can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bepridil.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Bepridil is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Bepridil.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Bepridil.Approved
CyclopenthiazideBepridil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Bepridil.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bepridil.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Bepridil is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Bepridil.Investigational
DarifenacinThe metabolism of Bepridil can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Bepridil can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Bepridil.Approved, Investigational
DelaprilBepridil may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Bepridil can be decreased when combined with Delavirdine.Approved
DeserpidineBepridil may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Desflurane.Approved
DesipramineThe metabolism of Bepridil can be decreased when combined with Desipramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bepridil.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Bepridil.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bepridil is combined with Diclofenamide.Approved
diethylnorspermineBepridil may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Bepridil.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Bepridil is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Bepridil is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Bepridil can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Bepridil is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Bepridil.Approved
DosulepinThe metabolism of Bepridil can be decreased when combined with Dosulepin.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Bepridil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bepridil.Approved, Investigational
DronedaroneThe metabolism of Bepridil can be decreased when combined with Dronedarone.Approved
DuloxetineBepridil may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Bepridil.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bepridil.Approved
EfavirenzThe serum concentration of Bepridil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Bepridil.Approved
EfonidipineBepridil may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe metabolism of Bepridil can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Bepridil is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Bepridil.Approved, Vet Approved
EnalaprilatBepridil may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Bepridil.Experimental
EpanololBepridil may increase the hypotensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Bepridil.Approved
EprosartanEprosartan may increase the hypotensive activities of Bepridil.Approved
ErythromycinThe metabolism of Bepridil can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Bepridil is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bepridil is combined with Etacrynic acid.Approved
EtravirineThe serum concentration of Bepridil can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bepridil.Approved
FelodipineFelodipine may increase the hypotensive activities of Bepridil.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Bepridil.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Bepridil.Experimental
Ferulic acidBepridil may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Bepridil is combined with Fimasartan.Approved, Investigational
FluconazoleThe serum concentration of Bepridil can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Bepridil.Approved
FluoxetineThe metabolism of Bepridil can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Bepridil.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Bepridil is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Bepridil can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Bepridil.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Bepridil.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bepridil.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Bepridil is combined with Furosemide.Approved, Vet Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Bepridil.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Bepridil.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Bepridil.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Bepridil.Approved
GuanazodineBepridil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Bepridil.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Bepridil.Approved, Investigational
GuanoclorBepridil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBepridil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBepridil may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Bepridil.Experimental
HaloperidolThe metabolism of Bepridil can be decreased when combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Bepridil.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Bepridil is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Bepridil.Experimental
HexamethoniumBepridil may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Bepridil.Approved, Investigational
HexobarbitalThe metabolism of Bepridil can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Bepridil.Experimental
HydralazineHydralazine may increase the hypotensive activities of Bepridil.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bepridil.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Bepridil.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Bepridil is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Bepridil is combined with Imipramine.Approved
IndapamideIndapamide may increase the hypotensive activities of Bepridil.Approved
IndenololBepridil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Bepridil can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Bepridil.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Bepridil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bepridil.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Bepridil.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bepridil.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Bepridil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Bepridil can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bepridil is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bepridil is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Bepridil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Bepridil.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Bepridil.Approved, Investigational
JosamycinThe metabolism of Bepridil can be decreased when combined with Josamycin.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Bepridil.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Bepridil.Approved, Investigational
KitasamycinThe metabolism of Bepridil can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Bepridil.Approved
LacidipineBepridil may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Bepridil.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bepridil.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Bepridil.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Bepridil is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Levobupivacaine.Approved, Investigational
LevodopaBepridil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Bepridil is combined with Levosimendan.Approved, Investigational
LinsidomineBepridil may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Bepridil.Approved, Investigational
LofexidineBepridil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Bepridil can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Bepridil can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Bepridil is combined with Losartan.Approved
LovastatinThe risk or severity of adverse effects can be increased when Bepridil is combined with Lovastatin.Approved, Investigational
LumefantrineThe metabolism of Bepridil can be decreased when combined with Lumefantrine.Approved
MacitentanBepridil may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineBepridil may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Bepridil is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Bepridil.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Bepridil.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Bepridil.Experimental
MethadoneThe metabolism of Bepridil can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Bepridil is combined with Methazolamide.Approved
MethohexitalThe metabolism of Bepridil can be increased when combined with Methohexital.Approved
MethoserpidineBepridil may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Bepridil can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Bepridil is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Bepridil.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bepridil.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bepridil.Approved, Investigational
MethylphenobarbitalThe metabolism of Bepridil can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Bepridil.Approved
MetolazoneMetolazone may increase the hypotensive activities of Bepridil.Approved
MetoprololThe risk or severity of adverse effects can be increased when Bepridil is combined with Metoprolol.Approved, Investigational
MetyrosineBepridil may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Bepridil.Experimental
MibefradilBepridil may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Bepridil.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Bepridil.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Bepridil can be decreased when combined with Midostaurin.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Bepridil.Approved
MinaprineMinaprine may increase the hypotensive activities of Bepridil.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bepridil.Approved
MirabegronThe metabolism of Bepridil can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Bepridil.Investigational
MivacuriumBepridil may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Bepridil.Approved
MoexiprilMoexipril may increase the hypotensive activities of Bepridil.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Bepridil.Approved, Investigational
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Bepridil.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Bepridil is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Bepridil.Approved, Investigational
MuzolimineBepridil may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Bepridil.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Bepridil is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Bepridil is combined with Nadolol.Approved
NafcillinThe metabolism of Bepridil can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bepridil.Approved
NaftopidilBepridil may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bepridil.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Bepridil.Approved
NebivololBepridil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Bepridil is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Bepridil can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Bepridil.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Bepridil.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Nifedipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Bepridil.Experimental
NiguldipineBepridil may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Bepridil.Investigational
NilotinibThe metabolism of Bepridil can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineBepridil may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Bepridil.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Bepridil.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Bepridil.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitroglycerin.Approved, Investigational
NitroprussideBepridil may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Bepridil.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Bepridil.Approved, Vet Approved
ObinutuzumabBepridil may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bepridil.Withdrawn
OleandomycinThe metabolism of Bepridil can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Bepridil.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Bepridil.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Bepridil.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Bepridil.Approved
OxprenololBepridil may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Bepridil is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Bepridil.Investigational
PanobinostatThe serum concentration of Bepridil can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Bepridil is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Bepridil.Approved
ParoxetineThe metabolism of Bepridil can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bepridil.Approved
Peginterferon alfa-2bThe serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololBepridil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Bepridil.Approved
PentobarbitalThe metabolism of Bepridil can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Bepridil.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bepridil.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Bepridil.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Bepridil.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bepridil.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Bepridil.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Bepridil.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bepridil.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Bepridil.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Bepridil.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Bepridil.Withdrawn
PindololPindolol may increase the hypotensive activities of Bepridil.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Pipamperone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Bepridil.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Bepridil is combined with Pitavastatin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Bepridil.Withdrawn
Platelet Activating FactorBepridil may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideBepridil may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Bepridil.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bepridil is combined with Pramipexole.Approved, Investigational
PravastatinThe risk or severity of adverse effects can be increased when Bepridil is combined with Pravastatin.Approved
PrazosinThe risk or severity of adverse effects can be increased when Bepridil is combined with Prazosin.Approved
PrimidoneThe metabolism of Bepridil can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Bepridil.Approved
PromazineThe metabolism of Bepridil can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Bepridil is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Bepridil is combined with Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bepridil.Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Bepridil.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Bepridil is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Bepridil.Approved, Investigational
QuinidineThe metabolism of Bepridil can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Bepridil.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Bepridil.Experimental
RamiprilRamipril may increase the hypotensive activities of Bepridil.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bepridil.Approved, Investigational
RapacuroniumBepridil may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Bepridil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bepridil is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Bepridil.Approved
RescinnamineBepridil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Bepridil is combined with Reserpine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Bepridil.Approved
RifabutinThe serum concentration of Bepridil can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Bepridil can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bepridil can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bepridil.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Bepridil.Investigational
RiociguatBepridil may increase the hypotensive activities of Riociguat.Approved
RisperidoneBepridil may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Bepridil can be decreased when combined with Ritonavir.Approved, Investigational
RituximabBepridil may increase the hypotensive activities of Rituximab.Approved
RolapitantThe metabolism of Bepridil can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Bepridil can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Ropivacaine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Bepridil is combined with Rosuvastatin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Bepridil is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Bepridil.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Bepridil.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bepridil.Approved, Vet Approved
SaprisartanBepridil may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirBepridil may increase the arrhythmogenic activities of Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Bepridil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bepridil.Approved, Investigational, Vet Approved
SelexipagBepridil may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Bepridil.Approved
SertralineThe metabolism of Bepridil can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bepridil.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Bepridil is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Bepridil.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Bepridil.Approved, Investigational
SitaxentanBepridil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Bepridil is combined with Sodium Nitrite.Approved
SolithromycinThe metabolism of Bepridil can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Bepridil is combined with Sotalol.Approved
SpiraprilBepridil may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Spironolactone.Approved
StiripentolThe metabolism of Bepridil can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bepridil is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Bepridil.Approved
TadalafilTadalafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
TalinololBepridil may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Bepridil.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Bepridil.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Bepridil.Approved, Withdrawn
TelithromycinThe metabolism of Bepridil can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Bepridil.Approved, Investigational
TemocaprilBepridil may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Bepridil.Approved
TerbinafineThe metabolism of Bepridil can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Bepridil.Approved
TerlipressinBepridil may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineBepridil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Bepridil is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineBepridil may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Bepridil can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Bepridil can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Bepridil can be decreased when combined with Thioridazine.Approved, Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Bepridil.Approved
TiboloneBepridil may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Bepridil can be decreased when combined with Ticlopidine.Approved
TicrynafenBepridil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Bepridil is combined with Timolol.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Bepridil.Approved
TipranavirThe serum concentration of Bepridil can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Tizanidine.Approved
TolazolineTolazoline may increase the hypotensive activities of Bepridil.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bepridil is combined with Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Bepridil.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Bepridil.Approved, Vet Approved
TolonidineBepridil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Bepridil.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bepridil.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Bepridil.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Bepridil.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bepridil.Experimental
TranylcypromineThe metabolism of Bepridil can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Bepridil.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bepridil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bepridil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Bepridil is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Bepridil.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Bepridil.Approved, Investigational
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Bepridil.Approved, Investigational
TylosinThe metabolism of Bepridil can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Ubidecarenone.Approved, Experimental
UdenafilUdenafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
UnoprostoneBepridil may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Bepridil.Investigational
ValsartanValsartan may increase the hypotensive activities of Bepridil.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bepridil.Approved
VenlafaxineThe metabolism of Bepridil can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Bepridil is combined with Verapamil.Approved
VincamineBepridil may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Bepridil.Approved, Investigational
VinpocetineBepridil may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Bepridil.Approved, Investigational
XipamideBepridil may increase the hypotensive activities of Xipamide.Experimental
XylometazolineBepridil may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bepridil.Approved, Vet Approved
ZiprasidoneThe metabolism of Bepridil can be decreased when combined with Ziprasidone.Approved
ZofenoprilBepridil may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
  • Alcohol may further decrease blood pressure and increase dizziness and drowsiness
  • Take with food to reduce nausea.

References

Synthesis Reference

Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".

General References
Not Available
External Links
Human Metabolome Database
HMDB15374
KEGG Compound
C06847
PubChem Compound
2351
PubChem Substance
46506353
ChemSpider
2261
BindingDB
78577
ChEBI
3061
ChEMBL
CHEMBL1008
Therapeutic Targets Database
DAP000525
PharmGKB
PA164754755
IUPHAR
2337
Guide to Pharmacology
GtP Drug Page
HET
BEP
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bepridil
ATC Codes
C08EA02 — Bepridil

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)128Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".
water solubilitySlightly solubleNot Available
logP5.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00655 mg/mLALOGPS
logP5.33ALOGPS
logP5.49ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.71 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.12 m3·mol-1ChemAxon
Polarizability43.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9859
Blood Brain Barrier+0.9003
Caco-2 permeable+0.5593
P-glycoprotein substrateSubstrate0.7013
P-glycoprotein inhibitor IInhibitor0.7951
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6774
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5495
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8462
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5636
Ames testNon AMES toxic0.67
CarcinogenicityNon-carcinogens0.8688
BiodegradationNot ready biodegradable0.9938
Rat acute toxicity2.4903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.536
hERG inhibition (predictor II)Inhibitor0.796
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylbenzamines
Alternative Parents
Dialkylarylamines / Benzylamines / Aniline and substituted anilines / Aralkylamines / N-alkylpyrrolidines / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylbenzamine / Benzylamine / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Aralkylamine / N-alkylpyrrolidine / Pyrrolidine / Tertiary amine / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amine, pyrrolidines (CHEBI:3061)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1A
Uniprot ID
O00555
Uniprot Name
Voltage-dependent P/Q-type calcium channel subunit alpha-1A
Molecular Weight
282362.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Kovacic H, Gallice P, Crevat A: Inhibition of sodium pump by bepridil. An in vitro and microcalorimetric study. Biochem Pharmacol. 1992 Oct 20;44(8):1529-34. [PubMed:1329768]
  2. Raess BU, Record DM: Inhibition of erythrocyte Ca2(+)-pump by Ca2+ antagonists. Biochem Pharmacol. 1990 Dec 1;40(11):2549-55. [PubMed:2148481]
  3. Smith SJ, England PJ: The effects of reported Ca2+ sensitisers on the rates of Ca2+ release from cardiac troponin C and the troponin-tropomyosin complex. Br J Pharmacol. 1990 Aug;100(4):779-85. [PubMed:2207500]
  4. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  5. Fuchs J, Mainka L, Reifart N, Zimmer G: Effects of bepridil on heart mitochondrial membrane and the isolated rat heart preparation. Arzneimittelforschung. 1986 Feb;36(2):209-12. [PubMed:2938592]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modul...
Gene Name
KCNQ1
Uniprot ID
P51787
Uniprot Name
Potassium voltage-gated channel subfamily KQT member 1
Molecular Weight
74697.925 Da
References
  1. Chouabe C, Drici MD, Romey G, Barhanin J: Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie. 2000 Jan-Feb;55(1):195-202. [PubMed:10860024]
  2. Yumoto Y, Horie M, Kubota T, Ninomiya T, Kobori A, Takenaka K, Takano M, Niwano S, Izumi T: Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock. J Cardiovasc Pharmacol. 2004 Feb;43(2):178-82. [PubMed:14716203]
  3. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M: HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol. 1998 Oct;54(4):695-703. [PubMed:9765513]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Troponin t binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC1
Uniprot ID
P63316
Uniprot Name
Troponin C, slow skeletal and cardiac muscles
Molecular Weight
18402.36 Da
References
  1. Abusamhadneh E, Abbott MB, Dvoretsky A, Finley N, Sasi S, Rosevear PR: Interaction of bepridil with the cardiac troponin C/troponin I complex. FEBS Lett. 2001 Sep 28;506(1):51-4. [PubMed:11591369]
  2. Wang X, Li MX, Sykes BD: Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J Biol Chem. 2002 Aug 23;277(34):31124-33. Epub 2002 Jun 11. [PubMed:12060657]
  3. MacLachlan LK, Reid DG, Mitchell RC, Salter CJ, Smith SJ: Binding of a calcium sensitizer, bepridil, to cardiac troponin C. A fluorescence stopped-flow kinetic, circular dichroism, and proton nuclear magnetic resonance study. J Biol Chem. 1990 Jun 15;265(17):9764-70. [PubMed:2351672]
  4. Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60. [PubMed:9525919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as...
Gene Name
PDE1B
Uniprot ID
Q01064
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
Molecular Weight
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cG...
Gene Name
PDE1A
Uniprot ID
P54750
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
Molecular Weight
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R: Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci. 2004 Jul;95(3):311-9. [PubMed:15272206]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 02:58